Prostaglandin E 2 (PGE 2 ) is mainly produced by osteoblasts in bone tissue, and acts as a potent stimulator of bone resorption. In osteoblasts, PGE 2 production was greatly stimulated by lipopolysaccharide (LPS) following the expression of cyclooxygenase (COX)-2 and membrane-bound PGE synthase (mPGES)-1 mRNA. In the coculture of mouse bone marrow cells and osteoblasts, LPS induced PGE production and osteoclast formation, and EP4 antagonist completely suppressed osteoclast formation, indicating that the PGE 2 -mediated EP4 signal is essential for LPS-induced osteoclast formation. Inflammatory bone diseases including periodontitis are known to be accompanied by bone loss with increased osteoclastogenesis. To examine the role of EP4-mediated PGE 2 action in periodontitis, we examined the effects of EP4 antagonist on LPS-induced bone resorption using mouse alveolar bone. In an organ culture of alveolar bone, LPS-induced bone resorbing activity and EP4 antagonist suppressed this LPS-induced bone resorption. In an experimental model of periodontitis, LPS was injected into the lower gingiva, and the bone mineral density of alveolar bone was measured. LPSinduced the loss of alveolar bone, which was recovered by the treatment with EP4 antagonist in vivo. Therefore, EP4 antagonist is a possible candidate for the therapy of inflammatory bone disease including periodontitis.
INTRODUCTION
Bone turnover is regulated by osteoclastic bone resorption and new bone formation mediated by osteoblasts. Recent studies have established that most bone-resorbing factors act on osteoblasts to induce receptor activator of NF-κB ligand (RANKL), a key molecule in osteoclast differentiation. [1] [2] [3] Prostaglandin E 2 (PGE 2 ) is produced mainly by osteoblasts in bone and stimulates bone resorption, especially during inflammation. PGE 2 synthesis is regulated in three metabolic steps: the release of arachidonic acid from membranous phospholipids by phospholipase A2 (PLA2), the conversion of arachidonic acid to PGH 2 by cyclooxygenase (COX), and the synthesis of PGE 2 by PGE synthase (PGES). [4] [5] [6] We have reported that the role of cytosolic PLA 2 (cPLA 2 ) expression in osteoblasts is to release arachidonic acid following PGE 2 production. 7, 8) Two isoforms of the COX enzyme, COX-1 and COX-2, have been identified, and previous studies have shown that COX-1 is a constitutive enzyme and COX-2 is an enzyme induced by various inflammatory stimuli. In osteoblasts, the expression of COX-2, but not COX-1, is markedly induced by interleukin-1 (IL-1). The terminal step in PGE 2 synthesis is catalyzed by PGES for the conversion of PGH 2 to PGE 2 . Recent studies have identified three forms of PGES: cytosolic PGES (cPGES), membrane-bound PGES (mPGES)-1, and mPGES-2. 6, [9] [10] [11] It is known that mPGES-1 is markedly induced by inflammatory stimuli, and functionally coupled with COX-2 for the accumulation of PGE 2 during inflammation.
There are four subtypes of PGE receptors, designated EP1, EP2, EP3, and EP4, that are encoded by different genes and expressed differently in each tissue. 12) The intracellular signaling differs among the receptor subtypes: EP1 is coupled to calcium mobilization, EP3 inhibits adenylate cyclase, whereas both EP2 and EP4 stimulate adenylate cyclase in various types of cells. Using knockout mice of respective EPs and specific EP agonists, we reported that PGE 2 stimulates bone resorption mainly by EP4 signal. 13, 14) EP4 agonist greatly stimulated the expression of RANKL in osteoblasts and induced osteoclast formation in mouse bone marrow cultures. 13 ) Therefore, it may be possible that blocking of the EP4 signal using EP4 antagonist prevents bone loss in inflammatory bone diseases.
Lipopolysaccharide (LPS) is a known pathogen leading to periodontitis, an infectious disease of mixed gram-negative bacteria that is associated with bone resorption. Toll-like receptors (TLRs) are known to play a critical role in innate immune responses in mammals, and 11 members of the TLR family (TLR1-TLR11) have been identified. 15) The TLRs are thought to be receptors for the recognition of various ligands, including bacterial components and nucleic acids that are involved in host defense mechanisms against pathogens. 15) Previous studies have shown that TLR4 is the most essential LPS receptor for signal transduction. 16) Not only immune systems, but also infectious diseases such as periodontitis, are thought to be involved in LPS-induced inflammation and the ensuing tissue destruction.
In the present study, we examined the effects of EP4 antagonist on LPS-induced osteoclast formation and destruction of alveolar bone, and suggest that blockage of the EP4 signal is a new therapeutic approach for inflammatory bone disease including periodontitis.
MATERIALS AND METHODS
Animals and Reagents --Newborn and 6-weekold mice of ddy strains were obtained from Japan SLC Inc. (Shizuoka, Japan).
All procedures were performed in accordance with the institutional guidelines for animal research. LPS (Escherichia coli 055:B5) was purchased from Difco Laboratories (Detroit, MI, U.S.A.). PGE 2 was obtained from Sigma (St. Louis, MO, U.S.A.). EP4 antagonist (ONO-AE3-208) was prepared in Ono Pharmaceutical Co., Ltd. Osaka, Japan. Culture of Primary Mouse Osteoblastic Cells --Primary osteoblastic cells were isolated from newborn mouse calvariae after five routine sequential digestions with 0.1% collagenase and 0.2% dispase. 7) Osteoblastic cells collected from fractions 2-5 were combined and cultured in α-modified minimum essential medium (αMEM), supplemented with 10% fetal calf serum (FCS) at 37 • C under 5% CO 2 in air. Measurement of PGE 2 Content --The concentrations of PGE 2 in the cultured medium were determined using an enzyme immunoassay (EIA) (Amersham, Aylesbury, U.K.). The antibody had the following cross-reactivity when calculated using the bound/free ratio: PGE 2 , 100%; PGE 1 , 7.0%; 6-keto-PGF 1 α, 5.4%; PGF 2 α, 4.3%; and PGD 2 , 1.0%. Osteoclast Formation in Coculture of Mouse Bone Marrow Cells and Osteoblasts --Bone marrow cells (3 × 10 6 cells) were isolated from 6-week-old mice and cocultured with the primary osteoblastic cells (1 × 10 4 cells) in 1 mL of αMEM containing 10% FCS. After being cultured for 7 days, the cells were stained for tartrate-resistant acid phosphatase (TRAP), and TRAP-positive multinucleated cells were counted as osteoclasts. reverse transcriptase (RT)-PCR Analysis --Total RNA was extracted from cultured cells using the acid guanidium-phenol-chloroform method, and cDNA was synthesized from 5 µg of total RNA by reverse transcriptase using PCR. 17) The primers in the PCR for the mouse COX-1, COX-2, mPGES-1, cPGES, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were used as reported previously. 17) The PCR product was run on a 1.5% agarose gel and stained with ethidium bromide. Bone-resorbing Activity in Organ Culture of Mandibular Alveolar Bone --Mandibular alveolar bone was collected from mouse lower gingivae under a microscope, and cultured for 24 hr in BGJb containing 1 mg/ml of bovine serum albumin. After 24 hr, alveolar bone was transferred into new medium with or without LPS, and cultured for 5 days. The concentration of calcium in the conditioned medium was measured by the ocresolphthalein complexon (OCPC) method. 14) The bone-resorbing activity was expressed as an increase in medium calcium, as shown in previous studies. 14) Treatment with LPS in Mice --As a model for experimental periodontitis, LPS (25 µg) was injected into six-week-old mouse lower gingivae on days 0, 2, and 4. As the control, PBS was injected into the lower gingivae. Mandibular alveolar bone was collected 7 days after the first injection.
Radiographic Analysis --The bone mineral density (BMD) of mandibular alveolar bone was measured by dual X-ray absorptiometry (model DCS-600R; Aloka, Tokyo, Japan), as reported previously. 7) The bone mineral content (BMC) of the femurs was closely correlated with the ash weight. 7) The BMD was calculated by dividing the BMC of the measured area by the area. Statistical Analysis --The data are expressed as the means ± SEM. The significance of differences was analyzed using Student's t-test.
RESULTS

LPS Induces COX-2 and mPGES-1 mRNAs in Mouse Osteoblasts to Produce PGE
We performed RT-PCR to examine the effects of LPS on the mRNA expression of COX-1, COX-2, cPGES, and mPGES-1 in mouse primary osteoblasts (Fig. 1A) . LPS markedly induced the mRNA expression of COX-2 and mPGES-1 in osteoblasts at 3 hr. The expression of COX-1 and cPGES mRNAs was detected in osteoblasts and its expression was not affected by LPS. The level of PGE 2 in the conditioned medium of mouse osteoblasts cultured in medium containing 10% FCS was measured at 24 hr, and we detected a marked elevation of PGE 2 in the conditioned medium of mouse osteoblasts treated with LPS (Fig. 1B) .
Effects of EP4 Antagonist on LPS-induced Osteoclast Formation in Cocultures of Mouse Bone Marrow Cells and Osteoblasts
We next examined the effects of LPS on osteoclast formation and PGE 2 production in cocultures of mouse osteoblasts and bone marrow cells. Adding LPS to the cocultures markedly induced osteoclast formation and PGE 2 production, both of which were completely suppressed by adding indomethacin, an inhibitor of PG synthesis (Fig. 2) . When EP4 antagonist was added to the cocultures, LPS-induced osteoclast formation was completely suppressed, and the level of PGE 2 in conditioned medium was not changed (Fig. 2) . Therefore, the EP4 signal is essential for osteoclast formation induced by LPS in the coclutures.
EP4 Antagonist Recovers LPS-induced Bone Loss of Mouse Alveolar Bone in a Model for Periodontitis
Periodontitis is a typical inflammatory bone dis-
Fig. 1. Effects of LPS on PGE 2 Production and mRNA Expression of COX-1, COX-2, mPGES-1, and cPGES in Mouse Osteoblasts
(A) Mouse primary osteoblasts were cultured for 3 hr with or without 10 ng/ml of LPS, and total RNA was extracted. RT-PCR was performed using respective primers for mouse COX-1, COX-2, mPGES-1, cPGES, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (B) Osteoblasts were cultured for 24 hr with or without 10 ng/ml of LPS, and the concentration of PGE 2 in the culture medium was determined using EIA. Data are expressed as the means ± SEM of 3 wells. Significantly different from the control without LPS, * p < 0.001.
ease accompanying severe alveolar bone loss. To examine the mechanism of the pathogenesis of periodontitis, we recently developed a new experimental model for periodontitis. 17) When mandibular alveolar bone was collected from mice, and cultured with or without LPS to detect bone resorption, we could detect an increase in bone-resorbing activity by treatment with LPS in alveolar bone ex vivo. EP4 antagonist, 0.01-1 µM, dose-dependently suppressed the bone-resorbing activity induced by LPS in the organ culture of mouse mandibular alveolar bone (Fig. 3A) . The level of PGE 2 was elevated by the LPS treatment, and not influenced by EP4 antagonist (Fig. 3B) . Indomethacin also suppressed LPS-induced PGE 2 production and bone-resorbing activity in the cultures (data not shown). In in vivo experiments, LPS was injected into the gingiva in the lower mandible, and alveolar bone was collected from mice on day 7 for the measurement of BMD by dual X-ray absorptiometry. LPS administration induced a significant decrease in BMD of mandibular alveolar bone (Fig. 4) . Treatment with EP4 antagonist in the lower mandible recovered the bone loss induced by LPS in a dose-dependent manner (Fig. 4) .
DISCUSSION
PGE 2 production by osteoblasts is regulated in three metabolic steps: the release of arachi- 
Fig. 4. EP4 Antagonist Recovers the LPS-induced Bone Loss of Mandibular Alveolar Bone In Vivo
LPS or PBS was injected into the gingiva in the lower mandible of mice, as described in the Materials and Methods, and the alveolar bone was collected from mice on day 7 for the measurement of BMD. Significantly different from control mice injected with PBS, * p < 0.05, * * p < 0.001, and # p < 0.001 versus LPS. Data are expressed as the means ± SEM of four mice. donic acid from the membranous phospholipids by cPLA 2 α, the conversion of arachidonic acid to PGH 2 by COX-2, and the synthesis of PGE 2 by PGES. We have reported that cPLA 2 α expression in osteoblasts is indispensable to the arachidonic acid release for PGE 2 synthesis and bone resorption, using cPLA 2 α-deficient mice. 7) COX-2 is known to be induced by cytokines, such as IL-1 in osteoblasts. Recent studies have indicated that mPGES-1 is an inducible terminal enzyme for PGE 2 biosynthesis, and its expression is linked to COX-2 induced by inflammatory cytokines in various cells. 6) In the present study, LPS markedly induced the mRNA expression of COX-2 and mPGES-1. Therefore, PGE 2 production by osteoblasts may be regulated by the sequential pathway of cPLA 2 α-COX-2-mPGES-1.
TLR4 has been reported to be the most essential LPS receptor for signal transduction. 16) To understand the pathway of LPS-induced PGE 2 production in osteoblasts, we used C3H/HeJ mice with mutated Tlr4. Osteoblasts from C3H/HeJ mice did not respond to LPS, and PGE 2 production was not altered. Also, LPS-induced bone loss in the femur was impaired in C3H/HeJ mice. 17) Thus, LPS binds to TLR4 on osteoblasts, and directly induces the expression of COX-2 and mPGES-1 for PGE 2 synthesis, leading to subsequent osteoclast formation.
It is well known that PGE 2 acts on osteoblasts and induces the expression of RANKL to elicit osteoclastogenesis. We have reported that PGE 2 could not induce bone resorption in organ cultures of mouse calvariae collected from EP4-null mice, and that EP4 agonist stimulates RANKL expression in osteoblasts and osteoclast formation in bone marrow cultures. 13, 14) In the present study, we clearly showed the effects of EP4 antagonist on osteoclast formation induced by LPS in the cocultures of mouse bone marrow cells and osteoblasts. We also detected the suppressive effects of EP4 antagonist on bone resorbing activity in mouse calvarial cultures (data not shown). Therefore, EP4 antagonist may prevent bone loss associated with inflammation.
In the previous study, we demonstrated a new model for mouse periodontitis associated with a loss of alveolar bone, which is induced by LPS administration to an ex vivo organ culture and in vivo injection to alveolar bone. The model successfully showed bone loss induced by LPS. In the present study, EP4 antagonist suppressed the LPS-induced loss of alveolar bone in an organ culture of mouse alveolar bone, and in an in vivo model of periodontitis (Figs. 3 and 4 ). Salvi and Lang 18) have reviewed evidence from animal experiments and clinical trials documenting that selective and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) were responsible for the stabilization of periodontal conditions by reducing the rate of alveolar bone resorption. In our model, like EP4 antagonist, indomethacin also suppressed alveolar bone loss induced by LPS (data not shown). Therefore, the application of EP4 antagonist and/or NSAIDs may help to protect against the loss of alveolar bone in periodontal diseases.
In the present study, we clearly showed that EP4 antagonist suppressed LPS-induced osteoclast formation and alveolar bone resorption, and that EP4 antagonist prevented the destruction of mouse mandibular alveolar bone. The LPS-TLR4-COX-2-mPGES-1-EP4 pathway may be critical for PGE 2 production and alveolar bone loss in the pathogenesis of periodontitis, and EP4 antagonist may be a promising therapeutic application to inflammatory bone disease.
